BR0214924A - Métodos para tratamento de distúrbios oftálmicos com antagonistas de receptor de aldosterona de epóxi esteroidal - Google Patents
Métodos para tratamento de distúrbios oftálmicos com antagonistas de receptor de aldosterona de epóxi esteroidalInfo
- Publication number
- BR0214924A BR0214924A BR0214924-9A BR0214924A BR0214924A BR 0214924 A BR0214924 A BR 0214924A BR 0214924 A BR0214924 A BR 0214924A BR 0214924 A BR0214924 A BR 0214924A
- Authority
- BR
- Brazil
- Prior art keywords
- receptor antagonists
- aldosterone receptor
- intraocular
- ophthalmic disorders
- methods
- Prior art date
Links
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 title abstract 6
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 title abstract 6
- 229940044551 receptor antagonist Drugs 0.000 title abstract 5
- 239000002464 receptor antagonist Substances 0.000 title abstract 5
- 239000004593 Epoxy Substances 0.000 title abstract 4
- 230000003637 steroidlike Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 4
- 229960001208 eplerenone Drugs 0.000 abstract 2
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 abstract 2
- 150000002500 ions Chemical class 0.000 abstract 2
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 208000001344 Macular Edema Diseases 0.000 abstract 1
- 206010025415 Macular oedema Diseases 0.000 abstract 1
- 206010067013 Normal tension glaucoma Diseases 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 239000003862 glucocorticoid Substances 0.000 abstract 1
- 230000004410 intraocular pressure Effects 0.000 abstract 1
- 201000002978 low tension glaucoma Diseases 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 201000010230 macular retinal edema Diseases 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 239000002395 mineralocorticoid Substances 0.000 abstract 1
- 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- 239000011591 potassium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- -1 sodium and potassium Chemical class 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 229940037128 systemic glucocorticoids Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
"MéTODOS PARA TRATAMENTO DE DISTúRBIOS OFTáLMICOS COM ANTAGONISTAS DE RECEPTOR DE ALDOSTERONA DE EPóXI ESTEROIDAL". A invenção descreve um método para tratar ou prevenir distúrbios oftálmicos, que compreende a administração de um ou mais antagonistas de receptor de aldosterona que contêm um componente de 9,11-epóxi, tal como eplerenona. O método resulta em uma redução de pressão intra-ocular, o que trata ou evita os distúrbios oftálmicos. entre os distúrbios estão hipertensão intra-ocular, glaucoma, glaucoma de baixa tensão, degeneração macular associada ao envelhecimento (AMD), edema macular e retinopatia diabética. Como os glicocorticóides e mineralocorticóides também causam a retenção de íons, tal como sódio e potássio, onde os receptores de aldosterona estão localizados, os antagonistas de receptor de aldosterona que contêm um componente de 9,11-epóxi, tal como eplerenona, também podem ser administrados para modular a concentração intra-ocular de íons. Desse modo, os antagonistas de receptor de aldosterona podem ser administrados para manter um meio iónico intra-ocular que é benéfico para a sobrevivência de células intra-oculares.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34103301P | 2001-12-12 | 2001-12-12 | |
| PCT/US2002/039807 WO2003049745A1 (en) | 2001-12-12 | 2002-12-12 | Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0214924A true BR0214924A (pt) | 2004-11-30 |
Family
ID=23335987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0214924-9A BR0214924A (pt) | 2001-12-12 | 2002-12-12 | Métodos para tratamento de distúrbios oftálmicos com antagonistas de receptor de aldosterona de epóxi esteroidal |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7015210B2 (pt) |
| EP (1) | EP1455795A1 (pt) |
| JP (1) | JP2005516914A (pt) |
| KR (1) | KR20040080439A (pt) |
| CN (1) | CN1774251A (pt) |
| AU (1) | AU2002346721A1 (pt) |
| BR (1) | BR0214924A (pt) |
| CA (1) | CA2469616A1 (pt) |
| IL (1) | IL162475A0 (pt) |
| MX (1) | MXPA04005674A (pt) |
| PL (1) | PL371128A1 (pt) |
| WO (1) | WO2003049745A1 (pt) |
| ZA (1) | ZA200404619B (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1469862A2 (en) * | 2002-01-30 | 2004-10-27 | Pharmacia Corporation | Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions |
| KR101160780B1 (ko) * | 2002-08-29 | 2012-06-27 | 산텐 세이야꾸 가부시키가이샤 | Ｒｈｏ 키나아제 억제제 및 프로스타글란딘류를 포함하는 녹내장 치료제 |
| WO2004045644A1 (ja) * | 2002-11-18 | 2004-06-03 | Santen Pharmaceutical Co., Ltd. | Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤 |
| PT1905452E (pt) | 2005-07-12 | 2013-07-16 | Kowa Co | Agente para a prevenção ou tratamento do glaucoma |
| US7799331B2 (en) | 2005-08-04 | 2010-09-21 | Taro Pharmaceutical North America, Inc. | Oral suspension of prednisolone acetate |
| EP2170343A1 (en) * | 2007-05-31 | 2010-04-07 | Joseph Weinstock | Treatment of age-related macular degeneration |
| US8609729B2 (en) * | 2009-04-15 | 2013-12-17 | Sucampo Ag | Method for treating macular degeneration |
| RU2411946C1 (ru) * | 2009-07-06 | 2011-02-20 | Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) | Вископротектор для защиты интраокулярных тканей |
| EP2568986B1 (en) * | 2010-05-10 | 2016-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for the treatment of fluid accumulation in and/ or under the retina |
| EP2582365B1 (en) * | 2010-06-16 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions for stimulating reepithelialisation during wound healing |
| WO2016141182A1 (en) | 2015-03-03 | 2016-09-09 | Yee Richard W | Compositions and methods for treating ocular diseases |
| US11933786B2 (en) | 2015-03-30 | 2024-03-19 | Stcube, Inc. | Antibodies specific to glycosylated PD-L1 and methods of use thereof |
| US20180280414A1 (en) * | 2015-10-13 | 2018-10-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation |
| EP3436475A1 (en) | 2016-03-29 | 2019-02-06 | STCube & Co., Inc. | Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins |
| TN2016000259A1 (en) * | 2016-06-27 | 2017-10-06 | Rekik Raouf | Salbutamol (albuterol) eye protective medicament. |
| US11746152B2 (en) * | 2016-07-20 | 2023-09-05 | Stcube, Inc. | Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4177267A (en) | 1963-12-09 | 1979-12-04 | Crown Zellerbach | Enhancing tissue penetration of physiologically active steroidal agents with DMSC |
| US3711602A (en) | 1970-10-30 | 1973-01-16 | Crown Zellerbach Corp | Compositions for topical application for enhancing tissue penetration of physiologically active agents with dmso |
| US4559332A (en) | 1983-04-13 | 1985-12-17 | Ciba Geigy Corporation | 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof |
| US4552871A (en) | 1983-04-13 | 1985-11-12 | Ciba Geigy Corporation | Steroids of the 20-spiroxane series, processes for the manufacture thereof, pharmaceutical preparations containing such compounds and the use of the latter |
| US4670551A (en) | 1984-06-21 | 1987-06-02 | Ciba-Geigy Corporation | Epoxy steroids |
| FI902006A7 (fi) | 1987-10-21 | 1990-04-20 | Upjohn Co | Menetelmä renniini-inhibiittoreiden valmistamiseksi, jotka sisältävät 1-amino-2-hydroksi-2-heterosyklisen etyylitähteen |
| DE4023369A1 (de) | 1990-07-23 | 1992-01-30 | Thomae Gmbh Dr K | Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| DE4203872A1 (de) | 1992-02-11 | 1993-08-12 | Thomae Gmbh Dr K | Imidazo(1,2-a)pyridine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| US5529992A (en) | 1992-04-21 | 1996-06-25 | Curators Of The University Of Missouri | Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors |
| CA2125251C (en) | 1993-06-07 | 2005-04-26 | Yoshiyuki Inada | A pharmaceutical composition for angiotensin ii-mediated diseases |
| AU6039296A (en) | 1995-06-07 | 1996-12-30 | G.D. Searle & Co. | Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldoste rone antagonist |
| US6172054B1 (en) * | 1995-06-15 | 2001-01-09 | Alcon Laboratories, Inc. | Combination therapy for lowering and controlling intraocular pressure |
| US6011023A (en) * | 1997-08-27 | 2000-01-04 | Alcon Laboratories, Inc. | Angiostatic steroids |
| WO2001087284A2 (en) * | 2000-05-11 | 2001-11-22 | Pharmacia Corporation | Aldosterone antagonist composition for release during aldosterone acrophase |
| AU1604001A (en) | 2000-06-13 | 2001-12-24 | Pharmacia Corp | Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects |
| US20040235809A1 (en) | 2000-07-27 | 2004-11-25 | Alexander John C | Epoxy steroidal aldosterone antagonist and beta-adremergic antagonist combination therepy for treatment of congestive heart failure |
-
2002
- 2002-12-12 WO PCT/US2002/039807 patent/WO2003049745A1/en not_active Ceased
- 2002-12-12 EP EP02784791A patent/EP1455795A1/en not_active Withdrawn
- 2002-12-12 KR KR10-2004-7009160A patent/KR20040080439A/ko not_active Withdrawn
- 2002-12-12 PL PL02371128A patent/PL371128A1/xx not_active Application Discontinuation
- 2002-12-12 JP JP2003550794A patent/JP2005516914A/ja not_active Withdrawn
- 2002-12-12 IL IL16247502A patent/IL162475A0/xx unknown
- 2002-12-12 CN CNA028270533A patent/CN1774251A/zh active Pending
- 2002-12-12 AU AU2002346721A patent/AU2002346721A1/en not_active Abandoned
- 2002-12-12 US US10/317,650 patent/US7015210B2/en not_active Expired - Fee Related
- 2002-12-12 CA CA002469616A patent/CA2469616A1/en not_active Abandoned
- 2002-12-12 BR BR0214924-9A patent/BR0214924A/pt not_active IP Right Cessation
- 2002-12-12 MX MXPA04005674A patent/MXPA04005674A/es unknown
-
2004
- 2004-06-10 ZA ZA200404619A patent/ZA200404619B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL162475A0 (en) | 2005-11-20 |
| US20030158162A1 (en) | 2003-08-21 |
| EP1455795A1 (en) | 2004-09-15 |
| ZA200404619B (en) | 2005-06-10 |
| CN1774251A (zh) | 2006-05-17 |
| KR20040080439A (ko) | 2004-09-18 |
| WO2003049745A1 (en) | 2003-06-19 |
| MXPA04005674A (es) | 2004-10-15 |
| PL371128A1 (en) | 2005-06-13 |
| AU2002346721A1 (en) | 2003-06-23 |
| US7015210B2 (en) | 2006-03-21 |
| JP2005516914A (ja) | 2005-06-09 |
| CA2469616A1 (en) | 2003-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gibbs III et al. | Cellular actions of topiramate: blockade of kainate‐evoked inward currents in cultured hippocampal neurons | |
| Szabo et al. | Effects of serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition plus 5-HT2A receptor antagonism on the firing activity of norepinephrine neurons | |
| Stevens et al. | Dopaminergic and noradrenergic modulation of amphetamine-induced changes in auditory gating | |
| WO2007150018A3 (en) | Steroid-containing sustained release intraocular implants and related methods | |
| CA2367092A1 (en) | Method for treating and/or preventing retinal diseases with sustained release corticosteroids | |
| BR0112361A (pt) | Métodos para tratamento de condições oculares mediadas por inflamação | |
| BR0316203A (pt) | Uso de um agente antialérgico e um esteróide para tratar rinite alérgica | |
| UY28126A1 (es) | Uso de glucocorticoides selectivos para la superficie ocular en el tratamiento de la sequedad ocular | |
| TW200633709A (en) | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions | |
| MX9707569A (es) | Un metodo para el tratamiento de la degeneracion macular. | |
| MXPA03010146A (es) | Composiciones de lipidos hipotensivos (derivados de prostaglandina) y timolol, y metodos para usar las mismas. | |
| TW200833341A (en) | 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions | |
| BRPI0406879A (pt) | Dispositivo de liberação sustentada e método para a liberação ocular de agentes adrenérgicos | |
| MXPA04001187A (es) | Receptores de interleucina-1 en el tratamiento de enfermedades. | |
| BR0210241A (pt) | Piranoindazóis e seu uso no tratamento de glaucoma | |
| Oliveira et al. | Mercury effects on the contractile activity of isolated heart muscle | |
| Sharrow et al. | Calcineurin as a potential contributor in estradiol regulation of hippocampal synaptic function | |
| WO2010102031A3 (en) | Methods for treating ocular inflammatory diseases | |
| TW200511996A (en) | The use of steroids to treat persons suffering from ocular disorders | |
| BR0210238A (pt) | Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma | |
| BR0316040A (pt) | Composto, métodos para tratar doenças, para tratar edema macular, degeneração macular, aumentar a velocidade do sangue retinal e da cabeça do nervo óptico, aumentar a tensão de oxigênio retinal e do nervo óptico e/ou um efeito neuroprotetor, para prevenir a repolarização ou a hiperpolarização de uma célula de mamìfero contendo canal de potássio, e para tratar do diabete, e, composição | |
| MY134562A (en) | Methods and compositions to treat conditions associated with neovascularization | |
| BR9907715A (pt) | Composição oftálmica/método para tratamento de lesão córnea e/ou de estesia córnea deteriordada, sìndrome de olho seco, hipolarcrimação e uso de um inibidor de redutase de aldose | |
| MX2014004297A (es) | Composicion reticuladora mejorada, suministrada por iontoforesis, util para el tratamiento de queratocono. | |
| TW200501934A (en) | Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 7A. E 8A. ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011. |